| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Emeran A Mayer | |
| Sylvie Bradesi | |||
| Jeremy Herman | |||
| P2860 | cites work | Role for protease activity in visceral pain in irritable bowel syndrome | Q22241892 |
| Antidepressants for neuropathic pain | Q24243292 | ||
| Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome | Q24684839 | ||
| TRP channels: targets for the relief of pain | Q28290040 | ||
| Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. | Q30350561 | ||
| Functional GI disorders: from animal models to drug development | Q30433078 | ||
| Acid sensing ion channels 2 and 3 are required for inhibition of visceral nociceptors by benzamil. | Q33283124 | ||
| The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome | Q34173846 | ||
| Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders | Q34212933 | ||
| A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain | Q34464747 | ||
| The serotonin signaling system: from basic understanding to drug development for functional GI disorders | Q34604868 | ||
| Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system | Q34650861 | ||
| Systematic review on the management of irritable bowel syndrome in North America. | Q34993728 | ||
| Antidepressants for irritable bowel syndrome | Q35083805 | ||
| Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome | Q35596611 | ||
| Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice | Q35761007 | ||
| CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats | Q35761024 | ||
| Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities | Q72330659 | ||
| Inhibition of calcium currents in rat colon sensory neurons by K- but not mu- or delta-opioids | Q77716662 | ||
| Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders | Q80480784 | ||
| Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats | Q80624041 | ||
| Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota | Q81402999 | ||
| Pregabalin pharmacology and its relevance to clinical practice | Q35865172 | ||
| Bad news from the brain: descending 5-HT pathways that control spinal pain processing | Q35941703 | ||
| Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome | Q35954087 | ||
| Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. | Q36249747 | ||
| Noradrenergic pain modulation | Q36618448 | ||
| Mechanisms of hypersensitivity in IBS and functional disorders | Q36728934 | ||
| Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. | Q36735647 | ||
| Selective role for TRPV4 ion channels in visceral sensory pathways. | Q36823423 | ||
| Duloxetine and other antidepressants in the treatment of patients with fibromyalgia | Q36917022 | ||
| Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain | Q36930795 | ||
| Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation | Q36931162 | ||
| Irritable bowel syndrome in psychiatric perspectives: a comprehensive review | Q36945139 | ||
| Antidepressant agents for the treatment of chronic pain and depression | Q36982694 | ||
| Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials | Q36983944 | ||
| TRPV1: a new target for treatment of visceral pain in IBS? | Q37193228 | ||
| Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study | Q38961749 | ||
| Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome | Q39320067 | ||
| Effect of long-term treatment with octreotide on rectal sensitivity in patients with non-constipated irritable bowel syndrome | Q39332435 | ||
| A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome | Q39383290 | ||
| Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain | Q40201616 | ||
| Transient receptor potential vanilloid-4 has a major role in visceral hypersensitivity symptoms | Q42437606 | ||
| Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats | Q43323885 | ||
| Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. | Q43585980 | ||
| Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats | Q43929040 | ||
| Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. | Q44106362 | ||
| Differential effects of mu-, delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat. | Q44331144 | ||
| Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors | Q44333170 | ||
| Impaired Pressure Sensation in Mice Lacking TRPV4 | Q44401201 | ||
| Delayed stress-induced colonic hypersensitivity in male Wistar rats: role of neurokinin-1 and corticotropin-releasing factor-1 receptors | Q44654262 | ||
| Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome | Q44700491 | ||
| Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats | Q46325802 | ||
| Effect of E. coli Nissle 1917 on post-inflammatory visceral sensory function in a rat model | Q46509752 | ||
| Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension | Q46863112 | ||
| Capsaicin receptor (TRPV1) and non-erosive reflux disease | Q46931233 | ||
| Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. | Q48138289 | ||
| Divergent role for CRF1 and CRF2 receptors in the modulation of visceral pain. | Q51454045 | ||
| Pharmacological modulation of rectal tone alters perception of distention in humans. | Q51572966 | ||
| Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. | Q53184076 | ||
| Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
| Lack of colonic inflammation-induced acute visceral hypersensitivity to colorectal distension in Nav1.9 knockout mice | Q60413857 | ||
| Transient Receptor Potential Vanilloid Receptor Subtype 1 in Painful Bladder Syndrome and its Correlation With Pain | Q60731291 | ||
| Vanilloid receptor 1 immunoreactivity in inflamed human bowel | Q60731295 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 697-703 | |
| P577 | publication date | 2008-09-26 | |
| P1433 | published in | Current Opinion in Pharmacology | Q3007702 |
| P1476 | title | Visceral analgesics: drugs with a great potential in functional disorders? | |
| P478 | volume | 8 |
| Q37183034 | Comparative effects of α2δ-1 ligands in mouse models of colonic hypersensitivity. |
| Q38165173 | DA-9701: A New Multi-Acting Drug for the Treatment of Functional Dyspepsia |
| Q89013977 | NaV1.1 inhibition can reduce visceral hypersensitivity |
| Q38191576 | Neuroanatomy of lower gastrointestinal pain disorders |
| Q35587841 | P2X₇ receptor of rat dorsal root ganglia is involved in the effect of moxibustion on visceral hyperalgesia. |
| Q52614686 | Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. |
| Q35087100 | Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities |
| Q42142075 | The κ-opioid receptor agonist U-50488 blocks Ca2+ channels in a voltage- and G protein-independent manner in sensory neurons |
| Q36729089 | Warming Moxibustion Relieves Chronic Visceral Hyperalgesia in Rats: Relations to Spinal Dynorphin and Orphanin-FQ System |
Search more.